Array Biopharma Company Profile (NASDAQ:ARRY)

About Array Biopharma (NASDAQ:ARRY)

Array Biopharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARRY
  • CUSIP: 04269X10
  • Web: www.arraybiopharma.com
Capitalization:
  • Market Cap: $1.41 billion
  • Outstanding Shares: 170,800,000
Average Prices:
  • 50 Day Moving Avg: $8.18
  • 200 Day Moving Avg: $9.26
  • 52 Week Range: $2.97 - $13.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.29
  • P/E Growth: -1.11
Sales & Book Value:
  • Annual Revenue: $41.51 million
  • Price / Sales: 34.03
  • Book Value: $0.16 per share
  • Price / Book: 51.69
Profitability:
  • EBIDTA: ($96,300,000.00)
  • Net Margins: -58.57%
  • Return on Assets: -49.54%
Debt:
  • Debt-to-Equity Ratio: 2.26%
  • Current Ratio: 4.10%
  • Quick Ratio: 4.10%
Misc:
  • Average Volume: 4.14 million shs.
  • Beta: 2.12
  • Short Ratio: 4.49
 

Frequently Asked Questions for Array Biopharma (NASDAQ:ARRY)

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.05. The company earned $33.28 million during the quarter, compared to analyst estimates of $38.28 million. The business's revenue for the quarter was down 22.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) EPS. View Array Biopharma's Earnings History.

Where is Array Biopharma's stock going? Where will Array Biopharma's stock price be in 2017?

8 brokerages have issued twelve-month price targets for Array Biopharma's stock. Their predictions range from $7.00 to $15.00. On average, they expect Array Biopharma's share price to reach $11.38 in the next year. View Analyst Ratings for Array Biopharma.

What are analysts saying about Array Biopharma stock?

Here are some recent quotes from research analysts about Array Biopharma stock:

  • 1. Cowen and Company analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)
  • 2. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (1/31/2017)

Are investors shorting Array Biopharma?

Array Biopharma saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 19,794,836 shares, an increase of 10.1% from the April 13th total of 17,983,716 shares. Based on an average daily volume of 2,465,514 shares, the short-interest ratio is presently 8.0 days. Currently, 11.7% of the shares of the stock are sold short.

Who are some of Array Biopharma's key competitors?

Who owns Array Biopharma stock?

Array Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (0.00%), VANGUARD GROUP INC (10.05%), Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.86%) and Pinnacle Associates Ltd. (0.00%). Company insiders that own Array Biopharma stock include Charles M Baum and Redmile Group, Llc. View Institutional Ownership Trends for Array Biopharma.

Who sold Array Biopharma stock? Who is selling Array Biopharma stock?

Array Biopharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Teachers Advisors LLC, Metropolitan Life Insurance Co. NY, Credit Suisse AG, Candriam Luxembourg S.C.A., AXA, Sphera Funds Management LTD. and TIAA CREF Investment Management LLC. Company insiders that have sold Array Biopharma stock in the last year include Charles M Baum and Redmile Group, Llc. View Insider Buying and Selling for Array Biopharma.

Who bought Array Biopharma stock? Who is buying Array Biopharma stock?

Array Biopharma's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Cambiar Investors LLC, Canada Pension Plan Investment Board, Goldman Sachs Group Inc., MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. View Insider Buying and Selling for Array Biopharma.

How do I buy Array Biopharma stock?

Shares of Array Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Array Biopharma stock cost?

One share of Array Biopharma stock can currently be purchased for approximately $8.27.

Analyst Ratings

Consensus Ratings for Array Biopharma (NASDAQ:ARRY) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $11.38 (37.55% upside)

Analysts' Ratings History for Array Biopharma (NASDAQ:ARRY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/6/2017Jefferies Group LLCSet Price TargetBuy$8.00HighView Rating Details
5/3/2017JPMorgan Chase & Co.UpgradeNeutral -> Overweight$9.00 -> $10.00LowView Rating Details
3/20/2017Cowen and CompanyLower Price TargetOutperform$14.00HighView Rating Details
2/9/2017Cantor FitzgeraldSet Price TargetBuy$13.00N/AView Rating Details
2/3/2017Stifel NicolausBoost Price TargetBuy$8.00 -> $13.00N/AView Rating Details
1/30/2017Leerink SwannDowngradeOutperform -> Market Perform$11.00N/AView Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetBuy$15.00N/AView Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$7.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Array Biopharma (NASDAQ:ARRY)
Earnings by Quarter for Array Biopharma (NASDAQ:ARRY)
Earnings History by Quarter for Array Biopharma (NASDAQ:ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Array Biopharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($0.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.21)($0.22)
Q2 20173($0.27)($0.20)($0.22)
Q3 20173($0.31)($0.22)($0.25)
Q4 20173($0.29)($0.21)($0.25)
Q1 20181($0.22)($0.22)($0.22)
Q2 20181($0.23)($0.23)($0.23)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Array Biopharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Array Biopharma (NASDAQ:ARRY)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 88.58%
Insider Trades by Quarter for Array Biopharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array Biopharma (NASDAQ:ARRY)
Insider Trades by Quarter for Array Biopharma (NASDAQ:ARRY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.00View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Array Biopharma (NASDAQ:ARRY)
Latest Headlines for Array Biopharma (NASDAQ:ARRY)
Source:
DateHeadline
americanbankingnews.com logoArray Biopharma Inc (ARRY) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 22 at 7:56 AM
americanbankingnews.com logoLeerink Swann Weighs in on Array Biopharma Inc's FY2017 Earnings (ARRY)
www.americanbankingnews.com - May 17 at 9:10 AM
finance.yahoo.com logoEdited Transcript of ARRY earnings conference call or presentation 10-May-17 1:00pm GMT
finance.yahoo.com - May 16 at 8:44 PM
americanbankingnews.com logoSunTrust Banks Brokers Lift Earnings Estimates for Array Biopharma Inc (ARRY)
www.americanbankingnews.com - May 15 at 8:52 AM
americanbankingnews.com logoFY2017 Earnings Forecast for Array Biopharma Inc (ARRY) Issued By Jefferies Group
www.americanbankingnews.com - May 12 at 1:18 PM
seekingalpha.com logoArray BioPharma's (ARRY) CEO Ron Squarer on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 9:02 PM
fool.com logoHere's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today - Motley Fool
www.fool.com - May 11 at 4:00 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Array Biopharma and Verastem
finance.yahoo.com - May 11 at 4:00 PM
americanbankingnews.com logoJefferies Group Weighs in on Array Biopharma Inc's Q1 2018 Earnings (ARRY)
www.americanbankingnews.com - May 11 at 1:30 PM
americanbankingnews.com logoFY2017 EPS Estimates for Array Biopharma Inc (ARRY) Lifted by SunTrust Banks
www.americanbankingnews.com - May 11 at 11:42 AM
americanbankingnews.com logo$30.03 Million in Sales Expected for Array Biopharma Inc (ARRY) This Quarter
www.americanbankingnews.com - May 11 at 10:26 AM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Short Interest Up 10.1% in April
www.americanbankingnews.com - May 11 at 7:12 AM
finance.yahoo.com logoArray Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove Daunting
finance.yahoo.com - May 10 at 8:48 PM
finance.yahoo.com logoHere's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today
finance.yahoo.com - May 10 at 3:48 PM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Issues Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - May 10 at 3:32 PM
finance.yahoo.com logoArray BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017
finance.yahoo.com - May 10 at 9:12 AM
finance.yahoo.com logoArray BioPharma reports 3Q loss
finance.yahoo.com - May 10 at 9:12 AM
finance.yahoo.com logoInvestor Network: Array BioPharma Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 9:12 AM
finance.yahoo.com logoArray BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma
finance.yahoo.com - May 9 at 8:39 PM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 9 at 6:24 PM
prnewswire.com logoArray BioPharma Announces Strategic Collaboration with Merck - PR Newswire (press release)
www.prnewswire.com - May 9 at 9:10 AM
nasdaq.com logoArray BioPharma To Collaborate With Merck To Study Binimetinib & Keytruda
www.nasdaq.com - May 8 at 10:38 AM
streetinsider.com logoArray Biopharma (ARRY) Enters Strategic Collaboration with Merck (MRK) for Treatment of Metastatic Colorectal Cancer
www.streetinsider.com - May 8 at 10:38 AM
americanbankingnews.com logoArray Biopharma Inc (ARRY) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 8:32 AM
americanbankingnews.com logoArray Biopharma (ARRY) Earning Somewhat Critical Press Coverage, Analysis Shows
www.americanbankingnews.com - May 3 at 12:37 PM
nasdaq.com logoArray BioPharma Breaks Below 200-Day Moving Average - Notable for ARRY
www.nasdaq.com - May 3 at 9:55 AM
finance.yahoo.com logoArray Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017
finance.yahoo.com - May 3 at 9:55 AM
americanbankingnews.com logoArray Biopharma (ARRY) Earning Somewhat Negative Media Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 8:06 AM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:29 AM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:28 AM
streetinsider.com logoArray Biopharma (ARRY) Appoints Shalini Sharp to Board - StreetInsider.com
www.streetinsider.com - April 28 at 9:39 PM
americanbankingnews.com logoArray Biopharma (ARRY) Given Daily Coverage Optimism Rating of 0.18
www.americanbankingnews.com - April 26 at 4:52 PM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 25 at 11:05 AM
americanbankingnews.com logoArray Biopharma (ARRY) Given Media Sentiment Rating of 0.44
www.americanbankingnews.com - April 23 at 10:17 AM
nasdaq.com logoArray BioPharma Enters Oversold Territory (ARRY) - Nasdaq
www.nasdaq.com - April 21 at 8:41 PM
finance.yahoo.com logoTrading 5 Hot Charts Set to Break Out Soon for Profit
finance.yahoo.com - April 20 at 3:41 PM
americanbankingnews.com logoArray Biopharma (ARRY) Receives Coverage Optimism Rating of 0.04
www.americanbankingnews.com - April 20 at 2:42 PM
americanbankingnews.com logo Analysts Expect Array Biopharma Inc (ARRY) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - April 18 at 10:20 PM
americanbankingnews.com logoArray Biopharma (ARRY) Receiving Somewhat Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 17 at 4:02 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen - Yahoo Finance
finance.yahoo.com - April 17 at 3:34 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen
finance.yahoo.com - April 17 at 9:04 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Unlikely to Impact Array Biopharma (ARRY) Stock Price
www.americanbankingnews.com - April 13 at 3:52 PM
americanbankingnews.com logoShort Interest in Array Biopharma Inc (ARRY) Increases By 13.0%
www.americanbankingnews.com - April 13 at 7:39 AM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Downgraded by Vetr Inc.
www.americanbankingnews.com - April 9 at 9:19 AM
nasdaq.com logoDo Options Traders Know Something About Array BioPharma (ARRY) Stock We Don't?
www.nasdaq.com - April 7 at 3:39 PM
finance.yahoo.com logoDo Options Traders Know Something About Array BioPharma (ARRY) Stock We Don't?
finance.yahoo.com - April 7 at 3:39 PM
americanbankingnews.com logoArray Biopharma's (ARRY) Buy Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - April 4 at 8:38 AM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Director Sells $231,750.00 in Stock
www.americanbankingnews.com - March 30 at 7:52 PM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 30 at 12:58 PM
americanbankingnews.com logoArray Biopharma Inc (ARRY) Upgraded by Vetr Inc. to "Strong-Buy"
www.americanbankingnews.com - March 30 at 12:40 AM

Social

Chart

Array Biopharma (ARRY) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff